Ataxion
Cambridge
About Ataxion
Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases. Located in Cambridge, Massachusetts, Ataxion was founded in April 2013 out of the Atlas Venture seed program by Dr. Josh Resnick and Atlas Venture Development Corporation Managing Director and Ataxion Board Member David Grayzel, MD.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $17.0M
- Funding stage: M&A
- Last round: Series A (Mar 2014)
- Website: ataxiontherapeutics.com
- Phone: (617)588-2644
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Canonical: https://fsome.com/organization/ataxion-898218 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.